Ophthalmology – Ocular Surface Squamous Neoplasia (OSSN)

Basics

Description

Ocular surface squamous neoplasia (OSSN) describes a spectrum of dysplastic and malignant squamous epithelial lesions involving the:

• Conjunctiva
• Cornea
• Limbus

The spectrum includes:

• Mild epithelial dysplasia
• Moderate/severe dysplasia
• Carcinoma in situ
• Invasive squamous cell carcinoma (SCC)

The modern concept is that OSSN represents a continuum from intraepithelial disease to stromal invasion.

⸻

Key Pathologic Distinction

Intraepithelial OSSN

Abnormal squamous cells remain confined above the epithelial basement membrane.

This includes:

• Mild dysplasia
• Moderate dysplasia
• Severe dysplasia
• Carcinoma in situ

Historically these lesions were often called:

Conjunctival intraepithelial neoplasia (CIN)

⸻

Invasive Squamous Cell Carcinoma

Invasive SCC occurs when atypical epithelial cells:

Breach the basement membrane and invade the underlying substantia propria or deeper tissues.

Advanced tumors may invade:

• Sclera
• Cornea
• Anterior chamber
• Orbit

Regional or distant metastasis is uncommon but possible.

⸻

Epidemiology

OSSN is one of the most common malignant tumors of the ocular surface.

Incidence varies markedly by:

• Geographic region
• Ultraviolet exposure
• HIV prevalence
• Population demographics

It is more common in:

• Older adults in temperate regions
• Younger adults in high-UV regions with HIV-associated disease

⸻

Risk Factors

Important risk factors include:

• Chronic ultraviolet-B exposure
• Increasing age
• Male sex in many populations
• Light skin pigmentation
• Smoking
• HIV infection
• Systemic immunosuppression
• Organ transplantation
• Xeroderma pigmentosum
• Chronic ocular surface disease

⸻

HPV

Human papillomavirus, particularly high-risk types such as:

• HPV 16
• HPV 18

has been detected in some OSSN lesions.

However:

The strength of the association varies between studies and geographic populations.

HPV is not considered necessary for development of OSSN.

⸻

Genetics and Molecular Biology

UV-induced DNA damage is believed to be an important mechanism.

Molecular alterations may involve:

• TP53
• Cell-cycle dysregulation
• Abnormal epithelial proliferation

Chronic UV exposure can produce characteristic DNA damage within ocular surface epithelial cells.

⸻

Pathophysiology

OSSN develops through progressive epithelial dysplasia.

A simplified sequence is:

UV or other carcinogenic injury → epithelial DNA damage → dysplasia → carcinoma in situ → invasive SCC

Immunosuppression can reduce normal immune surveillance and accelerate tumor development.

⸻

Associated Conditions

Important associations include:

• HIV/AIDS
• Organ transplantation
• Chronic systemic immunosuppression
• Xeroderma pigmentosum
• Atopic disease
• Other UV-related cutaneous malignancies

⸻

Prevention

Risk reduction includes:

• UV-blocking sunglasses
• Brimmed hats
• Smoking cessation
• Appropriate management of immunosuppression when possible

No strategy completely prevents OSSN.

⸻

Clinical Presentation

Patients may be asymptomatic or report:

• Ocular irritation
• Foreign-body sensation
• Redness
• Visible conjunctival lesion
• Persistent “pterygium”
• Decreased vision if the cornea or visual axis is involved

⸻

Typical Location

OSSN most commonly develops in the:

Interpalpebral limbal region

especially at the:

• Temporal limbus
• Nasal limbus

This distribution reflects chronic UV exposure.

⸻

Clinical Appearance

Conjunctival lesions may appear:

• Gelatinous
• Papilliform
• Leukoplakic
• Nodular
• Sessile
• Diffuse

They may be:

• Amelanotic
• Partially pigmented

⸻

Leukoplakia

A white surface plaque represents:

Hyperkeratosis

and is commonly seen in OSSN.

Marked leukoplakia may obscure underlying vascularity.

⸻

Corneal Extension

Corneal involvement often appears as:

• Gray-white epithelial opacity
• Translucent epithelial sheet
• Irregular or feathery margins
• Pseudopod-like epithelial extensions

Corneal disease remains superficial until invasive disease penetrates deeper layers.

⸻

Feeder Vessels

Prominent feeder vessels may occur.

Large or rapidly growing vessels may increase suspicion for:

• Invasive SCC
• Larger tumor burden

⸻

Signs Suggesting Invasion

Features concerning for invasive disease include:

• Fixed lesion
• Nodularity
• Marked thickness
• Scleral adherence
• Large feeder vessels
• Significant keratinization
• Intraocular inflammation
• Secondary glaucoma
• Orbital extension

⸻

Important Clinical Principle

CIN/carcinoma in situ and invasive SCC cannot be reliably distinguished by appearance alone.

Histopathology remains the gold standard when invasion is suspected.

⸻

Examination

A complete ocular surface examination should include:

• Visual acuity
• Slit-lamp evaluation
• Eyelid eversion
• Careful limbal examination
• Corneal assessment
• Palpation if a nodular lesion is present
• Regional lymph node examination in advanced disease

⸻

Gonioscopy

Gonioscopy is indicated when there is concern for intraocular extension.

Look for:

• Angle involvement
• Abnormal tissue
• Secondary glaucoma
• Anterior chamber invasion

⸻

Intraocular Invasion Warning

In a patient with known or suspected invasive OSSN, the combination of:

• Uveitis
• Elevated IOP
• Anterior chamber mass
• Persistent inflammation

should raise concern for:

Intraocular tumor extension

until proven otherwise.

⸻

Anterior Segment OCT

High-resolution anterior segment OCT is now one of the most useful noninvasive tools for OSSN.

Typical features include:

• Thickened hyperreflective epithelium
• Abrupt transition from normal to abnormal epithelium
• Sharp epithelial demarcation
• Shadowing in thick lesions

AS-OCT is useful for:

• Supporting diagnosis
• Defining tumor extent
• Monitoring response to topical therapy
• Detecting subclinical residual disease

⸻

Ultrasound Biomicroscopy

UBM may help when there is concern for:

• Deep stromal invasion
• Scleral involvement
• Intraocular extension
• Ciliary body involvement

It is especially useful for thicker limbal lesions.

⸻

Impression Cytology

Impression cytology may detect atypical epithelial cells.

It can be useful when:

• A noninvasive diagnostic approach is desired
• Disease is diffuse
• Topical therapy is being considered

However:

It cannot reliably assess stromal invasion.

Therefore, suspicious invasive lesions require biopsy.

⸻

Histopathology

Mild Dysplasia

Atypical cells occupy:

• Lower portions of the epithelium

with partial loss of maturation.

⸻

Severe Dysplasia / Carcinoma in Situ

Atypical cells involve:

Full thickness of the epithelium

without penetration through the basement membrane.

⸻

Invasive SCC

Shows:

• Squamous atypia
• Dyskeratosis
• Keratinization
• Invasion into underlying stroma

⸻

Rare Aggressive Variants

Mucoepidermoid Carcinoma

May demonstrate:

• Squamous differentiation
• Mucin-producing cells
• Greater tendency for deeper invasion

⸻

Spindle Cell / Sarcomatoid SCC

This variant may show:

• Spindle-shaped malignant cells
• More aggressive local behavior
• Higher metastatic potential

⸻

HIV Testing

Consider HIV testing particularly in:

• Younger patients
• Aggressive OSSN
• Multifocal disease
• Patients with other signs of immunosuppression

⸻

Differential Diagnosis

Benign Mimics

• Pterygium
• Pinguecula
• Papilloma
• Pyogenic granuloma
• Conjunctivitis
• Conjunctival nevus
• Limbal dermoid

⸻

Malignant Mimics

• Amelanotic melanoma
• Conjunctival melanoma
• Sebaceous carcinoma with pagetoid spread
• Lymphoma
• Metastatic tumor

⸻

OSSN vs Pterygium

Features favoring OSSN include:

• Irregular thickened epithelium
• Leukoplakia
• Prominent feeder vessel
• Gelatinous appearance
• Atypical corneal epithelial extension
• Abrupt epithelial transition on AS-OCT

A recurrent or atypical “pterygium” should be evaluated carefully.

⸻

Treatment Principles

Treatment depends on:

• Tumor size
• Thickness
• Location
• Circumferential limbal involvement
• Suspicion for invasion
• Prior recurrence
• Patient adherence
• Ability to follow closely

Modern treatment includes both:

• Surgical excision
• Topical medical therapy

Topical therapy is now an established treatment for many superficial OSSN lesions.

⸻

Surgical Excision

Localized or invasive-appearing lesions are often treated with:

Excisional biopsy using a no-touch technique

Goals include:

• Diagnostic confirmation
• Complete tumor removal
• Minimal manipulation of the tumor surface

⸻

No-Touch Technique

Typical principles include:

• Avoid direct manipulation of tumor
• Wide enough clinically clear conjunctival margins
• Superficial keratectomy for corneal component
• Removal of involved superficial sclera if necessary
• Adjunctive cryotherapy to conjunctival margins

⸻

Surgical Margins

Traditional excisions often use several millimeters of clinically normal tissue.

Margin width is individualized according to:

• Tumor size
• Suspicion of invasion
• Anatomic constraints

Excessively wide excision should be avoided when it would create unnecessary limbal stem cell deficiency.

⸻

Cryotherapy

Double freeze-thaw cryotherapy may be applied to:

• Conjunctival margins

to reduce recurrence from microscopic residual disease.

Care must be taken to avoid excessive tissue damage.

⸻

Ocular Surface Reconstruction

Large excisions may require:

• Amniotic membrane graft
• Conjunctival autograft
• Other ocular surface reconstruction

This helps reduce:

• Scarring
• Symblepharon
• Limbal stem cell deficiency

⸻

Topical Therapy

Topical treatment may be used:

• As primary therapy
• Before surgery to shrink a lesion
• After incomplete excision
• For recurrent disease
• For multifocal or diffuse disease

Major agents include:

• 5-fluorouracil
• Mitomycin C
• Interferon alfa-2b

⸻

5-Fluorouracil

Topical 5-FU 1% is widely used.

A common regimen is:

• Four times daily
• Given in treatment cycles

Advantages include:

• Relatively inexpensive
• Effective for broad epithelial disease
• Useful for diffuse lesions

Potential adverse effects include:

• Ocular irritation
• Epitheliopathy
• Conjunctivitis
• Keratitis

⸻

Mitomycin C

Topical MMC is highly effective.

Common concentrations include:

• 0.02%
• 0.04%

Usually given in cycles rather than continuously.

Potential toxicity includes:

• Significant conjunctivitis
• Epitheliopathy
• Punctal stenosis
• Limbal stem cell deficiency
• Scleral complications

Therefore:

MMC is effective but generally more toxic to the ocular surface than 5-FU or interferon.

⸻

Interferon Alfa-2b

Interferon alfa-2b has historically been used as:

• Topical drops
• Perilesional/subconjunctival injection

Advantages include relatively low ocular surface toxicity.

Adverse effects may include:

• Follicular conjunctivitis
• Local irritation
• Flu-like symptoms with injections

Availability has become limited in some regions, so 5-FU is often used more commonly today.

⸻

Choice of Topical Agent

A practical approach:

• 5-FU → inexpensive, effective, commonly available
• MMC → potent but more toxic
• Interferon → well tolerated but availability/cost may limit use

Choice depends on:

• Tumor characteristics
• Patient tolerance
• Cost
• Availability
• Physician experience

⸻

Medical Therapy and Invasive Disease

Topical agents treat:

Epithelial disease

but penetrate poorly into deeply invasive tumor.

Therefore:

Suspected invasive SCC should generally be biopsied and managed surgically and/or with additional oncologic therapy rather than topical therapy alone.

⸻

Monitoring During Topical Therapy

Follow-up should assess:

• Clinical tumor regression
• Corneal involvement
• Limbal disease
• Toxicity
• Residual subclinical epithelium

AS-OCT is particularly useful for detecting persistent disease beneath a clinically normal-looking surface.

⸻

Plaque Brachytherapy

Plaque radiotherapy may be considered for selected:

• Deep scleral invasion
• Intraocular extension
• Recurrent invasive disease

It is not routine for uncomplicated superficial OSSN.

⸻

Intraocular Invasion

Extensive intraocular involvement may require:

• Plaque radiotherapy
• Enucleation in severe cases

Management should involve ocular oncology.

⸻

Orbital Invasion

Extensive orbital spread may require:

• Radical surgery
• Radiation
• Systemic oncologic therapy

Exenteration is now reserved for selected advanced cases.

⸻

Regional Metastasis

Advanced SCC may spread to:

• Preauricular lymph nodes
• Submandibular lymph nodes
• Cervical nodes
• Parotid nodes

Distant metastasis is rare but can involve:

• Lung
• Bone
• Other organs

⸻

Lymph Node Evaluation

Regional node evaluation should be considered in:

• Large invasive SCC
• Recurrent aggressive disease
• Immunosuppressed patients
• Tumors with orbital invasion
• Poorly differentiated histology

⸻

Follow-Up

Long-term surveillance is necessary because recurrence may occur years later.

Follow-up is generally more frequent during the first:

1–2 years

when recurrence risk is highest.

⸻

During Topical Therapy

Patients may require review every:

4–8 weeks

depending on:

• Response
• Toxicity
• Treatment regimen

⸻

After Resolution

Once clinically resolved, patients should continue periodic examinations for:

• Local recurrence
• New OSSN
• Regional lymphadenopathy
• Treatment complications

Long-term follow-up is particularly important for:

• Immunosuppressed patients
• Recurrent disease
• Positive surgical margins
• Invasive SCC

⸻

Recurrence

Risk of recurrence is increased by:

• Positive surgical margins
• Multifocal disease
• Large tumor size
• Tarsal involvement
• Immunosuppression
• Lack of adjunctive therapy
• Invasive histology

Modern adjunctive topical therapy and cryotherapy have reduced recurrence rates compared with older excision-only series.

⸻

Prognosis

Overall prognosis is generally:

Excellent for localized epithelial disease

when properly treated.

Most lesions can be controlled with:

• Surgery
• Topical therapy
• Combination treatment

⸻

Poor Prognostic Features

More concerning features include:

• Large tumor
• Recurrent tumor
• Deep stromal invasion
• Scleral invasion
• Intraocular extension
• Orbital extension
• Aggressive histologic subtype
• Immunosuppression

⸻

Complications

Disease-Related

• Recurrence
• Corneal invasion
• Scleral invasion
• Intraocular extension
• Orbital invasion
• Rare regional or distant metastasis

⸻

Surgical Complications

Possible complications include:

• Limbal stem cell deficiency
• Conjunctival scarring
• Symblepharon
• Persistent epithelial defect
• Corneal scarring
• Dry eye

⸻

Medical Treatment Complications

Possible adverse effects include:

• Conjunctivitis
• Epitheliopathy
• Keratitis
• Limbal stem cell toxicity
• Punctal stenosis, particularly with MMC

⸻

Ophthalmology Pearls

• OSSN is a spectrum from epithelial dysplasia to invasive squamous cell carcinoma.
• The classic lesion occurs at the interpalpebral limbus and may be gelatinous, papilliform, or leukoplakic.
• Leukoplakia represents surface keratinization.
• UV exposure is one of the strongest established risk factors.
• HIV and systemic immunosuppression increase risk, particularly in younger patients.
• CIN/carcinoma in situ cannot reliably be distinguished from invasive SCC by appearance alone.
• High-resolution anterior segment OCT typically shows a thickened hyperreflective epithelium with an abrupt transition from normal tissue and is very useful for diagnosis and follow-up.
• Localized suspicious lesions are commonly managed with no-touch excisional biopsy plus adjunctive cryotherapy.
• 5-FU, mitomycin C, and interferon alfa-2b are established topical treatments for superficial OSSN.
• Topical chemotherapy treats epithelial disease but should not substitute for biopsy when deep invasion is suspected.
• Uveitis or secondary glaucoma in a patient with invasive OSSN should raise concern for intraocular extension.
• Positive margins, immunosuppression, and invasive disease increase recurrence risk.
• Long-term follow-up is required because recurrence may occur years after apparent cure.